INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community

Open-access resource includes Registry of Antiviral Compound Libraries to help catalyze drug discovery for priority viruses of pandemic and endemic concern

CAMBRIDGE, Mass., Nov. 4, 2025 /PRNewswire/ -- The INTREPID Alliance today announced the launch of the Antiviral Toolbox, an open-access resource to support the global research community in its efforts toward filling the gaps in antiviral R&D that is critical to global health security and the protection of communities worldwide. This curated platform provides easy access to a focused collection of tools and publications, including a Registry of Antiviral Compound Libraries, to help catalyze the identification and development of small-molecule antivirals.

Small-molecule antivirals are indispensable tools for rapid, scalable, and equitable responses to epidemic and pandemic threats.¹ INTREPID's latest review of the global antiviral R&D landscape reveals that beyond Coronaviridae, only 27 antiviral compounds are in clinical development to tackle 12 viral families and their multiple diseases of greatest pandemic concern. Furthermore, there are no clinical development efforts underway for 4 viral families of pandemic potential (Paramyxoviridae, Hantaviridae, Peribunyaviridae, and Togaviridae).^2,3

"Without increased focus and investment in antiviral drug development, the world is at risk of facing a devastating impact from future outbreaks of new and known viruses," said James Anderson, Executive Director of R&D Innovation at the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Chair of the INTREPID Alliance Board. "The Antiviral Toolbox can serve as a valuable resource to academic and industry researchers as well as other stakeholders involved in pandemic preparedness, providing essential tools to help accelerate innovation in antiviral R&D and fill the gaps in global preparedness aligned with the goals of the 100 Days Mission."

The key components within the INTREPID Alliance Antiviral Toolbox include:

• Registry of Antiviral Compound Libraries: A curated list of accessible compound libraries for antiviral screening sourced from publicly disclosed academic institutions, corporate, and commercial vendor listings.
• Antiviral Development Landscape: INTREPID's bi-annual landscape report and interactive pipeline, along with deep-dive topic reports, that provide a comprehensive analysis of small-molecule antiviral compounds in preclinical and clinical development globally.
• Drug Development Tools: Essential resources, including the published INTREPID Alliance Target Compound Profiles,⁴ Target Product Profiles,⁵ and cell and animal models for specific viral families, available to help drug discoverers and developers at all stages of research.
• Pro Bono Advisory Services: Opportunity for drug discoverers and developers to connect with INTREPID's team of experts to discuss potential strategies and approaches to address challenges along their drug development journey.

"The INTREPID Alliance Antiviral Toolbox comes at a critical time, especially for small biotechnology companies that have limited resources to advance their promising antiviral research," said John C. Pottage, Jr., M.D., Lead Scientific Consultant for the INTREPID Alliance. "Providing these scientific tools and connection points to open-access collections in one stop, along with the opportunity to access INTREPID's advisory services could make the difference between developers advancing versus shelving their compounds at critical inflection points."